{"id":90,"date":"2020-11-08T09:45:35","date_gmt":"2020-11-08T09:45:35","guid":{"rendered":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/?p=90"},"modified":"2021-12-10T02:35:14","modified_gmt":"2021-12-10T02:35:14","slug":"the-impact-of-covid-19-on-biopharmaceutical-rd-turn-crisis-into-opportunity","status":"publish","type":"post","link":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/the-impact-of-covid-19-on-biopharmaceutical-rd-turn-crisis-into-opportunity\/","title":{"rendered":"The Impact of COVID-19 on Biopharmaceutical R&#038;D\u2014Turn Crisis into Opportunity"},"content":{"rendered":"<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>COVID-19 Drug Development Status<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Pharma Intelligence Latest daily statics<\/strong><\/span><\/p>\n<ul style=\"list-style-type: disc;\">\n<li><span style=\"font-size: 14pt;\">456 R&amp;D pipeline drugs<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">2451 clinical trials<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\"><strong>The gap between experimentation and industry progress<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">These trials are largely sponsored by academia and government, and promoted by reusing drugs.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Few industry projects are at the clinical stage.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Drug pipeline<\/strong><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-91 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/1-300x213.png\" alt=\"\" width=\"489\" height=\"347\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/1-300x213.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/1-768x546.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/1.png 995w\" sizes=\"(max-width: 489px) 100vw, 489px\" \/>\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Treatment Paradigm<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Biopharmaceutical companies are developing multiple therapies at different speeds.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-92 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2-300x130.png\" alt=\"\" width=\"671\" height=\"291\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2-300x130.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2-1024x444.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2-768x333.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2-1536x666.png 1536w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/2.png 1691w\" sizes=\"(max-width: 671px) 100vw, 671px\" \/><\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Innovative R&amp;D<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">In the near future, biopharmaceutical companies will provide more effective treatments that are suitable for large stockpiles and for preventive use.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>The first new antiviral drugs entered clinical trials this summer.<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">The drugs are competing with a large number of existing tests.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">They still require community communication for verification that will continue throughout 2020.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">It can also be positioned as a preventive drug, providing a bridge for the wide supply of vaccines.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\"><strong>Vaccine is the most ideal and scalable treatment plan, attracting industry to work together for this.<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">The tight timetable condenses various research and development work.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Huge R&amp;D scale is to compensate for expected risks.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">About 170 projects cover 10 different vaccine technologies.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">The scale of production continues to expand to meet market demand.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>COVID-19 Drug Development Partnership<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">The industry is uniting and working together to tackle COVID-19. Biopharmaceutical companies not only cooperate with each other, but also cooperate with government agencies, non-governmental organizations, and academia to share resources and expertise.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Alliance<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">National Institute of Health: Accelerating COVID-19 treatment interventions and vaccine development.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Bill Gates Foundation: Accelerator for COVID-19 Therapy.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">World Health Organization: Access to COVID-19 tools (ACT) accelerator.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-93 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/3-300x144.png\" alt=\"\" width=\"459\" height=\"220\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/3-300x144.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/3-1024x492.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/3-768x369.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/3.png 1452w\" sizes=\"(max-width: 459px) 100vw, 459px\" \/><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Partnership<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Increasing number of R&amp;D alliances and licensing agreements.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Institutions like BARDA and CEPI also funded early research.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-94 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-300x243.png\" alt=\"\" width=\"414\" height=\"335\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-300x243.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-1024x830.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-768x622.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-1536x1245.png 1536w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/4-2048x1660.png 2048w\" sizes=\"(max-width: 414px) 100vw, 414px\" \/><\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Clinical Interruptions<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Community isolation and point-of-care disruptions can affect clinical operations.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Almost all biopharmaceutical and CRO companies have indicated that they will discontinue ongoing and planned clinical trials.<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Except for key areas of focus, new sites and patient recruitment are generally suspended.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Existing trials are still going on and will be modified if necessary to ensure continuity.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\">Although indicators now point to stabilization and recovery, the scale of the interrupted tests is difficult to quantify.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong> <img decoding=\"async\" loading=\"lazy\" class=\" wp-image-95 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/5-300x190.png\" alt=\"\" width=\"442\" height=\"280\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/5-300x190.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/5-1024x649.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/5-768x487.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/5.png 1319w\" sizes=\"(max-width: 442px) 100vw, 442px\" \/><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-96 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/6-300x196.png\" alt=\"\" width=\"444\" height=\"290\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/6-300x196.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/6-1024x669.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/6-768x502.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/6.png 1329w\" sizes=\"(max-width: 444px) 100vw, 444px\" \/><br \/>\n<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>\u00a0<\/strong><\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Focus on Trials Affected by COVID-19<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">There have been experimental disruptions in all areas of drug development.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Trialtrove notes that research has been subject to varying degrees of interference and that many studies have been able to continue, however, this influence is pervasive in many areas of biopharmaceuticals.<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Clinical stages &#8211; early, middle and critical stages are affected.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Treatment area &#8211; relative ranking is consistent with all ongoing trials.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Test sites &#8211; biased towards the US and the EU-5, and China and Japan were not listed the top 10.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-97 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/7-300x148.png\" alt=\"\" width=\"407\" height=\"201\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/7-300x148.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/7-768x380.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/7.png 869w\" sizes=\"(max-width: 407px) 100vw, 407px\" \/><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Cross-sectional View of A Trial Disturbed by COVID-19<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-98 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/8-300x175.png\" alt=\"\" width=\"485\" height=\"283\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/8-300x175.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/8-1024x598.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/8-768x449.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/8.png 1404w\" sizes=\"(max-width: 485px) 100vw, 485px\" \/><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-99 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/9-300x188.png\" alt=\"\" width=\"479\" height=\"300\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/9-300x188.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/9-1024x641.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/9-768x481.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/9.png 1293w\" sizes=\"(max-width: 479px) 100vw, 479px\" \/><strong><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-100 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/10-300x206.png\" alt=\"\" width=\"483\" height=\"332\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/10-300x206.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/10-1024x702.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/10-768x526.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/10.png 1248w\" sizes=\"(max-width: 483px) 100vw, 483px\" \/><\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>An Industry Response to Mitigate Clinical Disruption<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>How can biopharmaceutical companies maintain r&amp;d momentum during the COVID-19 pandemic?<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Biopharmaceutical companies must maintain as much continuity as possible to improve patient outcomes.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Interrupting trials delays access to new treatments, causing collateral damage, but also avoiding the possible increased risk of coronavirus exposure.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Move to Decentralized Virtual Trials<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Scientists are accelerating clinical trial innovation.<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Decentralized virtual trials offer the possibility of continuing clinical research by transferring medical points.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Industry acceptance rates are still low, but COVID-19 has sparked growing industry interest and concern.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Digital and virtual innovations in clinical trials include:<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Online consent forms, tied to electronic health records.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Decentralized care, including mobile clinics.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Patients report results and wearables.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Remote monitoring of telemedicine for patients.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Real-time tracking of clinical trials.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\">Broad benefits include cost, time, convenience, diversity, and resistance to COVID-19 destruction.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-105 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2020\/10\/11-300x168.png\" alt=\"\" width=\"493\" height=\"276\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2020\/10\/11-300x168.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2020\/10\/11-1024x572.png 1024w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2020\/10\/11-768x429.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2020\/10\/11.png 1307w\" sizes=\"(max-width: 493px) 100vw, 493px\" \/><\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 14pt;\"><strong>Diversity of Clinical Studies<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Expand trial scope and inclusion to speed up research.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Trial sponsors should also seek to further expand the scope of trials to accelerate the pace of clinical research.<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Wider geographic distribution: countries with low COVID-19 exposure, recovering\/resilient.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Looser inclusion criteria: comorbidity, age.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Patient demographics: for minority groups.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 14pt;\">This will accelerate the pace of clinical research and improve its quality\/applicability in different regions of the world.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Trade-offs are made in terms of sample homogeneity of introduced variables, which may require a larger sample size to achieve equivalent statistical efficacy.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Rationalization exclusion criteria. At the extreme, regulators need to receive real evidence.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\" wp-image-102 aligncenter\" src=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/12-300x254.png\" alt=\"\" width=\"457\" height=\"387\" srcset=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/12-300x254.png 300w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/12-768x651.png 768w, https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-content\/uploads\/2021\/12\/12.png 967w\" sizes=\"(max-width: 457px) 100vw, 457px\" \/><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>COVID-19 Drug Development Status Pharma Intelligence Latest daily statics 456 R&amp;D pipeline drugs 2451 clinical trials The gap between experimentation and industry progress These trials are largely sponsored by academia and government,<a class=\"moretag\" href=\"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/the-impact-of-covid-19-on-biopharmaceutical-rd-turn-crisis-into-opportunity\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":27,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/90"}],"collection":[{"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=90"}],"version-history":[{"count":3,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/90\/revisions"}],"predecessor-version":[{"id":107,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/90\/revisions\/107"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media\/27"}],"wp:attachment":[{"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=90"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=90"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sars-cov-2.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=90"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}